Literature DB >> 32370954

ACR Appropriateness Criteria® Dementia.

Gul Moonis1, Rathan M Subramaniam2, Anna Trofimova3, Judah Burns4, Julie Bykowski5, Santanu Chakraborty6, Kathryn Holloway7, Luke N Ledbetter8, Ryan K Lee9, Jeffrey S Pannell10, Jeffrey M Pollock11, William J Powers12, Robert P Roca13, Joshua M Rosenow14, Robert Y Shih15, Pallavi S Utukuri16, Amanda S Corey17.   

Abstract

Degenerative disease of the central nervous system is a growing public health concern. The primary role of neuroimaging in the workup of patients with probable or possible Alzheimer disease has typically been to exclude other significant intracranial abnormalities. In general, the imaging findings in structural studies, such as MRI, are nonspecific and have limited potential in differentiating different types of dementia. Advanced imaging methods are not routinely used in community or general practices for the diagnosis or differentiation of forms of dementia. Nonetheless, in patients who have been evaluated by a dementia expert, FDG-PET helps to distinguish Alzheimer disease from frontotemporal dementia. In patients with suspected dementia with Lewy bodies, functional imaging of the dopamine transporter (ioflupane) using SPECT may be helpful. In patients with suspected normal-pressure hydrocephalus, DTPA cisternography and HMPAO SPECT/CT brain may provide assessment. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2020 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Alzheimer disease; Appropriate Use Criteria; Appropriateness Criteria; Cognitive decline; Dementia with Lewy body; Frontotemporal dementia; Suspected idiopathic normal-pressure hydrocephalus; Vascular dementia

Mesh:

Year:  2020        PMID: 32370954     DOI: 10.1016/j.jacr.2020.01.040

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  5 in total

1.  Heuristic scoring method utilizing FDG-PET statistical parametric mapping in the evaluation of suspected Alzheimer disease and frontotemporal lobar degeneration.

Authors:  Jeremy N Ford; Elizabeth M Sweeney; Myrto Skafida; Shannon Glynn; Michael Amoashiy; Dale J Lange; Eaton Lin; Gloria C Chiang; Joseph R Osborne; Silky Pahlajani; Mony J de Leon; Jana Ivanidze
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-08-15

Review 2.  Therapy for Alzheimer's disease: Missing targets and functional markers?

Authors:  Milan Stoiljkovic; Tamas L Horvath; Mihály Hajós
Journal:  Ageing Res Rev       Date:  2021-03-09       Impact factor: 11.788

3.  Usefulness of Brain Positron Emission Tomography with Different Tracers in the Evaluation of Patients with Idiopathic Normal Pressure Hydrocephalous.

Authors:  Maria Vittoria Mattoli; Giorgio Treglia; Maria Lucia Calcagni; Annunziato Mangiola; Carmelo Anile; Gianluca Trevisi
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

4.  Diagnostic yield of diffusion-weighted brain MR imaging in patients with cognitive impairment: Large cohort study with 3,298 patients.

Authors:  Minjae Kim; Sang Yeong Kim; Chong Hyun Suh; Woo Hyun Shim; Jae-Hong Lee; Jeffrey P Guenette; Raymond Y Huang; Sang Joon Kim
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

Review 5.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.